Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

EMBO Mol Med. 2019 May;11(5):e10666. doi: 10.15252/emmm.201910666.

Abstract

Publication types

  • Published Erratum